Organophosphate Poisoning: Evidence‑Based Acute Management

Initial Emergency Therapy

• Administer atropine immediately (adults 1–2 mg IV; children 0.02 mg/kg IV, minimum 0.1 mg, maximum 0.5 mg) and double the dose every 5 minutes until full atropinization is achieved, while simultaneously giving a pralidoxime loading dose of 1–2 g IV followed by a continuous infusion, and start benzodiazepines for seizures. This rapid, combined regimen is the cornerstone of lifesaving treatment. [@1]
• Healthcare personnel must wear full personal protective equipment (PPE) before patient contact; secondary exposure from contaminated clothing, skin, or gastric contents has caused severe cholinergic crisis in staff requiring atropine, pralidoxime, and intubation. [@2]
• Remove all contaminated clothing and irrigate the skin copiously with soap and water for any external exposure. [@1]

Airway Management

• Perform early endotracheal intubation in patients with bronchorrhea, bronchospasm, altered mental status, or respiratory‑muscle weakness that threaten airway protection. [@1]
• Avoid succinylcholine and mivacurium for neuromuscular blockade because they are metabolized by cholinesterase and are contraindicated in organophosphate poisoning. [@1]

Atropine Therapy

• Typical cumulative atropine requirements are 10–20 mg in the first 2–3 hours, with severe cases needing up to 50 mg in the first 24 hours. [@2]
• After achieving atropinization, continue atropine as a continuous infusion at 10–20 % of the total loading dose per hour, not exceeding 2 mg/h in adults. [@2]
• Atropine‑induced tachycardia is an expected pharmacologic effect and is not a contraindication to continued dosing; withholding or reducing atropine because of tachycardia increases the risk of respiratory failure and death. [@2]

Pralidoxime (Oxime) Therapy

• Adults receive a 1–2 g pralidoxime IV loading dose administered slowly over 15–30 minutes, followed by a continuous infusion of 400–600 mg/h. [@1]
• Children receive 25–50 mg/kg IV loading dose over 15–30 minutes, followed by an infusion of 10–20 mg/kg/h. [@2]
• The American Heart Association gives pralidoxime a Class 2a recommendation with Level A evidence (“reasonable to use” with high‑quality supporting data). [@1]
• Oxime therapy should be started as early as possible—ideally within minutes to a few hours after exposure—before the organophosphate‑acetylcholinesterase complex “ages” and becomes irreversible. [@2]
• Do not withhold oximes when the class of poison (organophosphate vs. carbamate) is unknown; early administration is essential because the two poisonings are clinically indistinguishable. [@1]

Seizure Management

• Benzodiazepines are first‑line for seizures and agitation; diazepam 5–10 mg IV (adults) or 0.2 mg/kg IV (children) is preferred, with midazolam 2–5 mg IV (adults) or 0.05–0.1 mg/kg IV (children) as an alternative. [@1]

Monitoring and Complications

• Observe patients for at least 48–72 hours because delayed complications and relapses can occur, especially after ingestion where gastrointestinal absorption may continue. [@2]
• Intermediate syndrome may develop 24–96 hours after acute exposure, presenting as respiratory‑muscle weakness, proximal limb weakness, and cranial‑nerve palsies. [@2]
• Rhabdomyolysis is a recognized complication; serial measurement of creatine kinase and potassium is recommended for early detection. [@2]
• Myoglobinuric renal failure may follow severe rhabdomyolysis; management includes aggressive hydration, forced diuresis, and urine alkalinization. [@2]
• High‑dose atropine can cause fever and hallucinations; these adverse effects do not indicate treatment failure and should not prompt discontinuation of atropine. [@2]
• Continuous cardiac monitoring is advised for dysrhythmias, but dysrhythmias should not limit atropine dosing. [@2]

Common Pitfalls to Avoid

• Never delay atropine administration; it carries Class 1, Level A evidence as the immediate life‑saving intervention. [@1]
• Never use succinylcholine or mivacurium for intubation; they are absolutely contraindicated. [@1]
• Never withhold pralidoxime when the poison class is unknown; give it empirically. [@1]

Special Considerations for Carbamate Poisoning

• Management of carbamate poisoning follows the same algorithm as organophosphate poisoning (atropine, benzodiazepines, decontamination, and supportive care). [@4]
• Although carbamates spontaneously dissociate from acetylcholinesterase and do not cause “aging,” pralidoxime should still be administered when the poison class cannot be identified. [@1]

Management of Organophosphate Poisoning: Evidence‑Based Recommendations

Acute Respiratory Complications

• Respiratory failure caused by bronchorrhea, bronchospasm, and paralysis of the respiratory muscles is the leading cause of death during the immediate cholinergic crisis; early aggressive atropinization and prompt endotracheal intubation are required. American Society of Anesthesiologists recommendation. 1
• Upper‑airway obstruction may develop from paralysis of tongue and pharyngeal muscles, and delayed asphyxia from bilateral recurrent laryngeal nerve paralysis has been reported even after initial stabilization; vigilant airway monitoring is essential. American Society of Anesthesiologists recommendation. 1
• Pulmonary edema can arise from excessive muscarinic stimulation; aggressive atropinization and early mechanical ventilation are necessary to prevent fatal outcomes. American Society of Anesthesiologists recommendation. 1

Acute Neurological Complications

• Central nervous system acetylcholine accumulation produces seizures, anxiety, delirium, and altered mental status; benzodiazepines (e.g., diazepam) are the first‑line therapy. American Society of Anesthesiologists recommendation. 1

Musculoskeletal and Renal Complications

• Severe myonecrosis results from acetylcholine‑induced calcium influx into skeletal muscle, leading to myocyte death. American Society of Anesthesiologists recommendation. 1
• Rhabdomyolysis may follow muscle breakdown; serial monitoring of creatine kinase and potassium is essential to detect progression. American Society of Anesthesiologists recommendation. 1
• Myoglobinuric renal failure can develop after extensive rhabdomyolysis; treatment requires aggressive intravenous hydration, forced diuresis, and urine alkalinization when urine becomes reddish. American Society of Anesthesiologists recommendation. 1

Intermediate Syndrome (24–96 h Post‑Exposure)

• Between 24 and 96 hours after exposure, patients may develop paralysis of respiratory muscles, neck flexors, proximal limb muscles, and motor cranial nerves, even after successful treatment of the acute crisis; this syndrome responds poorly to additional atropine or pralidoxime. American Society of Anesthesiologists recommendation. 1
• The cornerstone of management is supportive respiratory care in an intensive‑care setting for several days, as antidotal therapy is ineffective. American Society of Anesthesiologists recommendation. 1
• Continuous positive airway pressure (CPAP) ventilation is often suboptimal in patients with a full stomach, bowel paralysis, or inability to cooperate; endotracheal intubation with mechanical ventilation is preferred in such cases. American Society of Anesthesiologists recommendation. 1

Secondary Exposure Prevention (Healthcare Workers)

• Healthcare personnel are at significant risk of secondary organophosphate poisoning from contaminated clothing, skin, and gastric contents; documented incidents required atropine, pralidoxime, and prolonged intubation (≥ 24 h). American College of Emergency Physicians recommendation. 2
• Full personal protective equipment (gloves, gowns, eye protection, and respiratory protection) must be used before any patient contact; failure to employ PPE has resulted in severe cholinergic crisis among staff. American College of Emergency Physicians recommendation. 2

Critical Clinical Pitfalls (Evidence‑Based Alerts)

• Resolution of the acute cholinergic crisis does not guarantee safety; intermediate syndrome can emerge up to four days later, necessitating continued observation. American Society of Anesthesiologists recommendation. 1
• Premature extubation should be avoided; patients must be fully awake, free of secretions, able to protect their airway, and demonstrate adequate spontaneous breathing before removal of the tube. American Society of Anesthesiologists recommendation. 1
• Muscle weakness after the acute phase should not automatically be attributed to residual cholinergic effects; when intermediate syndrome is present, supportive ventilation is required rather than escalation of antidote dosing. American Society of Anesthesiologists recommendation. 1

Management of Intermediate Syndrome after Organophosphate Poisoning

Critical Recognition and Overall Strategy

• The American Society of Anesthesiologists emphasizes that the cornerstone of intermediate syndrome (IMS) management is intensive‑care supportive respiratory care for several days, because atropine and pralidoxime are ineffective once IMS is established. Level of evidence: expert opinion 3

Respiratory Support

• Early endotracheal intubation is recommended when respiratory‑muscle weakness threatens airway protection or gas exchange; prompt mechanical ventilation prevents fatal respiratory arrest. Level of evidence: expert opinion 3

Neuromuscular Blockade Considerations

• Depolarizing agents (succinylcholine, mivacurium) must be avoided in organophosphate poisoning; if neuromuscular blockade is required for intubation or ventilator synchrony, non‑depolarizing agents such as rocuronium should be used at the minimal effective dose. Level of evidence: expert opinion 3

Monitoring Requirements

• Continuous close monitoring is mandatory and should include: Level of evidence: expert opinion 3

Supportive Care Measures

• Physiotherapy should be provided during prolonged ventilation to prevent contractures and preserve muscle function. Level of evidence: expert opinion 3
• Preventive measures for pressure ulcers and other complications of immobility are essential. Level of evidence: expert opinion 3
• Prophylactic antibiotics are not routinely indicated unless there is evidence of aspiration. Level of evidence: expert opinion 3

Clinical Pitfalls to Avoid

• Clinicians must not assume that resolution of the acute cholinergic crisis guarantees safety; IMS can appear up to 4 days after exposure, requiring continued observation for at least 48–72 hours post‑exposure. Level of evidence: expert opinion 3
• Extubation should be delayed until the patient is fully awake, free of secretions, able to protect the airway, and demonstrates adequate spontaneous breathing. Level of evidence: expert opinion 3
• Escalating atropine or pralidoxime in the presence of IMS is futile; supportive ventilation remains the only effective intervention. Level of evidence: expert opinion 3